A Focus on STRIVE: Sutter Health Leads its Largest-enrolling Clinical Trial to Date
SAN FRANCISCO – Several Sutter Health sites participated in STRIVE, a study that is evaluating a new tool for the detection of early-stage breast cancer. Begun in 2017 and now closed to enrollment, the study recruited the highest number of Sutter patients of any trials to date, regardless of therapeutic area.
The multicenter study will evaluate a new blood test potentially complementary to mammography for early detection of breast cancer. The test is being developed by GRAIL, Inc., and the study recruited women at mammography centers across Sutter Health and the Mayo Clinic.
“STRIVE has the potential to improve how we screen for breast cancer, and is one of the largest of its kind for a health system,” says Michael Rowbotham, MD, Chief Research Officer and VP, Sutter Health/ Scientific Director.
“This initiative is instrumental in evaluating how new technology might enhance early detection of breast cancer and other cancers,” says Steve Cummings, MD, California Pacific Medical Center Research Institute Senior Scientist, and principal investigator of the study. “Given its location in Northern California—one of the most diverse populations worldwide—Sutter Health research work with the STRIVE study could help pioneer breakthroughs in early diagnosis that may help improve patients’ experiences throughout the United States and beyond.”
Breast cancer that is found early is easier to treat successfully. Regular mammograms are the current standard of care for breast cancer screening. However, in some women, breast cancer can be difficult to detect with existing screening methods.
During the STRIVE Study, blood samples were collected from women who consented to participate in the study at the time of their mammogram. Blood samples will be analyzed for small pieces of cell-free tumor-derived nucleic acids. Women will be followed for at least five years after their screening mammogram.
According to the American Cancer Society, approximately 232,000 women in the United States are diagnosed with breast cancer annually, and more than 40,000 women die from the disease every year.
- The STRIVE study enrolled over 38,000 Sutter patients at 11 mammography sites over 20 months.
- All Sutter patients who were scheduled for an annual screening mammogram were eligible.
- Now in the follow-up phase at Sutter, STRIVE participants will be actively monitored for cancer outcomes through email and postcards, newsletter reminders and Electronic Medical Record surveillance.
- STRIVE illustrates Sutter’s coordinated efforts to improve cancer research and treatment outcomes for patients, and its collaboration in large, phase 1-3 national clinical studies sponsored by the National Cancer Institute (NCI) and the pharmaceutical industry.